Circulating Cell-free miRNA Expression and its Association with Clinicopathologic Features in Inflammatory and Non-Inflammatory Breast Cancer |
Hamdi, K
(Laboratory of Genetics, Immunology and Human Pathology, Faculty of Sciences, University of Tunis El Manar)
Blancato, J (Lombardi Comprehensive Cancer Center, Georgetown University Medical Center) Goerlitz, D (Lombardi Comprehensive Cancer Center, Georgetown University Medical Center) Islam, MD (Lombardi Comprehensive Cancer Center, Georgetown University Medical Center) Neili, B (Laboratory of Genetics, Immunology and Human Pathology, Faculty of Sciences, University of Tunis El Manar) Abidi, A (Laboratory of Genetics, Immunology and Human Pathology, Faculty of Sciences, University of Tunis El Manar) Gat, A (Laboratory of Genetics, Immunology and Human Pathology, Faculty of Sciences, University of Tunis El Manar) Ayed, F Ben (Department of Medical Oncology, Hannibal International Clinic) Chivi, S (Lombardi Comprehensive Cancer Center, Georgetown University Medical Center) Loffredo, CA (Lombardi Comprehensive Cancer Center, Georgetown University Medical Center) Jillson, I (Lombardi Comprehensive Cancer Center, Georgetown University Medical Center) Elgaaied, A Benammar (Laboratory of Genetics, Immunology and Human Pathology, Faculty of Sciences, University of Tunis El Manar) Marrakchi, R (Laboratory of Genetics, Immunology and Human Pathology, Faculty of Sciences, University of Tunis El Manar) |
1 | Anfossi S, Giordano A, Gao H, et al (2014). High serum miR-19a levels are associated with inflammatory breast cancer and are predictive of favorable clinical outcome in patients with metastatic HER2+ inflammatory breast cancer. PLoS One, 9, 83113. DOI |
2 | Chen C, Ridzon DA, Broomer AJ, et al (2005). Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res, 33, e179. DOI |
3 | Chen X, Ba Y, Ma L, et al (2008). Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res, 18, 997-1006. DOI |
4 | Cittelly DM, Das PM, Salvo VA, et al (2010). Oncogenic HER2{Delta}16 suppresses miR-15a/16 and deregulates BCL-2 to promote endocrine resistance of breast tumors. Carcinogenesis, 31, 2049-57. DOI |
5 | Cortez MA, Bueso-Ramos C, Ferdin J, et al (2011). MicroRNAs in body fluids--the mix of hormones and biomarkers. Nat Rev Clin Oncol, 8, 467-77. DOI |
6 | Croce CM (2009). Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet, 10, 704-14. DOI |
7 | Dawood S, Cristofanilli M (2011). Inflammatory breast cancer: what progress have we made? Oncol, 25, 264-73. |
8 | Dawood S, Merajver SD, Viens P, et al (2011). International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol, 22, 515-23. DOI |
9 | Fang Z, Tang J, Bai Y, et al (2015). Plasma levels of microRNA-24, microRNA-320a, and microRNA-423-5p are potential biomarkers for colorectal carcinoma. J Exp Clin Cancer Res, 34, 86. DOI |
10 | Gaziel-Sovran A, Segura MF, Di Micco R, et al (2011). miR- 30b/30d regulation of GalNAc transferases enhances invasion and immunosuppression during metastasis. Cancer Cell, 20, 104-18. DOI |
11 | Hagrass HA, Sharaf S, Pasha HF, et al (2015). Circulating microRNAs - a new horizon in molecular diagnosis of breast cancer. Genes Cancer, 6, 281-7. |
12 | Hamdi K, Goerlitz D, Stambouli N, et al (2014). miRNAs in Sera of Tunisian patients discriminate between inflammatory breast cancer and non-inflammatory breast cancer. Springerplus, 3, 636. DOI |
13 | Hatse S, Brouwers B, Dalmasso B, et al (2014). Circulating MicroRNAs as easy-to-measure aging biomarkers in older breast cancer patients: correlation with chronological age but not with fitness/frailty status. PLoS One, 9, 110644. DOI |
14 | Hausler SF, Keller A, Chandran PA, et al (2010). Whole bloodderived miRNA profiles as potential new tools for ovarian cancer screening. Br J Cancer, 103, 693-700. DOI |
15 | Heneghan HM, Miller N, Kelly R, et al (2010). Systemic miRNA-195 differentiates breast cancer from other malignancies and is a potential biomarker for detecting noninvasive and early stage disease. Oncologist, 15, 673-82. DOI |
16 | Huang Z, Huang D, Ni S, et al (2010). Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer, 127, 118-26. DOI |
17 | Kodahl AR, Lyng MB, Binder H, et al (2014). Novel circulating microRNA signature as a potential non-invasive multimarker test in ER-positive early-stage breast cancer: a case control study. Mol Oncol, 8, 874-83. DOI |
18 | Liu YX, Long XD, Xi ZF, et al (2014). MicroRNA-24 modulates aflatoxin B1-related hepatocellular carcinoma prognosis and tumorigenesis. Biomed Res Int, 2014, 482926. |
19 | Konishi H, Ichikawa D, Komatsu S, et al (2012). Detection of gastric cancer-associated microRNAs on microRNA microarray comparing pre-and post-operative plasma. Br J Cancer, 106, 740-7. DOI |
20 | Li X, Abdel-Mageed AB, Mondal D, et al (2013). MicroRNA expression profiles in differentiated thyroid cancer, a review. Int J Clin Exp Med, 6, 74-80. |
21 | Livak KJ, Schmittgen TD (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods, 25, 402-8. DOI |
22 | Lodes MJ, Caraballo M, Suciu D, et al (2009). Detection of cancer with serum miRNAs on an oligonucleotide microarray. PLoS One, 4, 6229. DOI |
23 | Lugli G, Cohen AM, Bennett DA, et al (2015). Plasma exosomal miRNAs in persons with and without alzheimer disease: altered expression and prospects for biomarkers. PLoS One, 10, 139233. |
24 | Luo Q, Li X, Li J, et al (2013). MiR-15a is underexpressed and inhibits the cell cycle by targeting CCNE1 in breast cancer. Int J Oncol, 43, 1212-8. DOI |
25 | Mitchell PS, Parkin RK, Kroh EM, et al (2008). Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA, 105, 10513-8. DOI |
26 | Nassar FJ, El Sabban M, Zgheib NK, et al (2014). miRNA as potential biomarkers of breast cancer in the Lebanese population and in young women: a pilot study. PLoS One, 9, 107566. DOI |
27 | Palmero EI, de Campos SG, Campos M, et al (2011). Mechanisms and role of microRNA deregulation in cancer onset and progression. Genet Mol Biol, 34, 363-70. DOI |
28 | Schwarzenbach H, Hoon DS, Pantel K (2011). Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer, 11, 426-37. DOI |
29 | Roth C, Rack B, Muller V, et al (2010). Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. Breast Cancer Res, 12, 90. DOI |
30 | Sayed D, Abdellatif M (2011). MicroRNAs in development and disease. Physiol Rev, 91, 827-87. DOI |
31 | Schwarzenbach H, Nishida N, Calin GA, et al (2014). Clinical relevance of circulating cell-free microRNAs in cancer. Nat Rev Clin Oncol, 11, 145-56. DOI |
32 | Shapira I, Oswald M, Lovecchio J, et al (2014). Circulating biomarkers for detection of ovarian cancer and predicting cancer outcomes. Br J Cancer, 110, 976-83. DOI |
33 | Shinden Y, Akiyoshi S, Ueo H, et al (2015). Diminished expression of MiR-15a is an independent prognostic marker for breast cancer cases. Anticancer Res, 35, 123-7. |
34 | Simpson RJ, Lim JW, Moritz RL, et al (2009). Exosomes: proteomic insights and diagnostic potential. Expert Rev Proteomics, 6, 267-83. DOI |
35 | Tomimaru Y, Eguchi H, Nagano H, et al (2012). Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma. J Hepatol, 56, 167-75. DOI |
36 | Van der Auwera I, Limame R, van Dam P, et al (2010). Integrated miRNA and mRNA expression profiling of the inflammatory breast cancer subtype. Br J Cancer, 103, 532-41. DOI |
37 | Wang F, Zheng Z, Guo J, et al (2010). Correlation and quantitation of microRNA aberrant expression in tissues and sera from patients with breast tumor. Gynecol Oncol, 119, 586-93. DOI |
38 | Wu Q, Wang C, Lu Z, et al (2012). Analysis of serum genomewide microRNAs for breast cancer detection. Clin Chim Acta, 413, 1058-65. DOI |
39 | Wu C, Wang C, Guan X, et al (2014). Diagnostic and prognostic implications of a serum miRNA panel in oesophageal squamous cell carcinoma. PLoS One, 9, 92292. DOI |
40 | Wu Q, Lu Z, Li H, et al (2011). Next-generation sequencing of microRNAs for breast cancer detection. J Biomed Biotechnol, 2011, 597145. |
41 | Yamauchi H, Woodward WA, Valero V, et al (2012). Inflammatory breast cancer: what we know and what we need to learn. Oncologist, 17, 891-9. DOI |
42 | Yan LX, Huang XF, Shao Q, et al (2008). MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA, 14, 2348-60. DOI |
43 | Zeng X, Xiang J, Wu M, et al (2012). Circulating miR-17, miR-20a, miR-29c, and miR-223 combined as non-invasive biomarkers in nasopharyngeal carcinoma. PLoS One, 7, 46367. DOI |
44 | Zhang G, Liu Z, Cui G, et al (2014). MicroRNA-486-5p targeting PIM-1 suppresses cell proliferation in breast cancer cells. Tumour Biol, 35, 11137-45. DOI |
45 | Zhu W, Qin W, Atasoy U, et al (2009). Circulating microRNAs in breast cancer and healthy subjects. BMC Res Notes, 2, 89. DOI |
![]() |